Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Age range
18 Years – 130 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia
Timeframe: Day 1 through Day 31
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Through 31 Days
Timeframe: Day 1 through Day 31
Number of Participants With TEAEs Through 91 Days
Timeframe: Day 1 through Day 91
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
Timeframe: Day 1 through Day 191
Number of Participants With Adverse Events of Special Interest (AESIs)
Timeframe: Day 1 through Day 191
Number of Participants With New Onset Chronic Diseases (NOCDs)
Timeframe: Day 1 through Day 191